{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:58:27Z","timestamp":1773939507018,"version":"3.50.1"},"reference-count":30,"publisher":"Spandidos Publications","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomed Rep"],"DOI":"10.3892\/br.2023.1627","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T09:26:38Z","timestamp":1685352398000},"source":"Crossref","is-referenced-by-count":5,"title":["Programmed death\u2011ligand 1 expression in tumor cells and tumor\u2011infiltrating lymphocytes are associated with depth of tumor invasion in penile cancer"],"prefix":"10.3892","volume":"19","author":[{"given":"Sakkarn","family":"Sangkhamanon","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natcha","family":"Kotano","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wichien","family":"Sirithanaphol","sequence":"additional","affiliation":[{"name":"Division of Urologic Surgery, Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ukrit","family":"Rompsaithong","sequence":"additional","affiliation":[{"name":"Division of Urologic Surgery, Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pakorn","family":"Kiatsopit","sequence":"additional","affiliation":[{"name":"Division of Urologic Surgery, Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aumkhae","family":"Sookprasert","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosin","family":"Wirasorn","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prin","family":"Twinprai","sequence":"additional","affiliation":[{"name":"Department of Radiology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyakarn","family":"Watcharenwong","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jarin","family":"Chindaprasirt","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,5,29]]},"reference":[{"key":"key20230628080225_b1-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.eururo.2014.10.017","article-title":"EAU guidelines on penile cancer: 2014 Update","volume":"67","author":"Hakenberg","year":"2015","journal-title":"Eur Urol"},{"key":"key20230628080225_b2-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.currproblcancer.2015.03.010","article-title":"Epidemiology of penile cancer","volume":"39","author":"Christodoulidou","year":"2015","journal-title":"Curr Probl Cancer"},{"issue":"891623","key":"key20230628080225_b3-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.891623","article-title":"Trends in incidence, mortality, and survival of penile cancer in the United States: A population-based study","volume":"12","author":"Deng","year":"2022","journal-title":"Front Oncol"},{"issue":"2965","key":"key20230628080225_b4-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-59831-5","article-title":"Profile of patients with penile cancer in the region with the highest worldwide incidence","volume":"10","author":"Vieira","year":"2020","journal-title":"Sci Rep"},{"issue":"e34874","key":"key20230628080225_b5-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.2196\/34874","article-title":"Global pattern and trends in penile cancer incidence: Population-based study","volume":"8","author":"Fu","year":"2022","journal-title":"JMIR Public Health Surveill"},{"key":"key20230628080225_b6-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N Engl J Med"},{"key":"key20230628080225_b7-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMe1205943","article-title":"Tumor immunotherapy directed at PD-1","volume":"366","author":"Ribas","year":"2012","journal-title":"N Engl J Med"},{"key":"key20230628080225_b8-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.3892\/or.2015.3933","article-title":"The prognostic significance of PD-L1 in bladder cancer","volume":"33","author":"Huang","year":"2015","journal-title":"Oncol Rep"},{"key":"key20230628080225_b9-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"key20230628080225_b10-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"499.e9","DOI":"10.1016\/j.urolonc.2018.07.003","article-title":"Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma","volume":"36","author":"Ueda","year":"2018","journal-title":"Urol Oncol"},{"issue":"962","key":"key20230628080225_b11-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00962","article-title":"Prognostic and clinicopathological significance of PD-L1 in patients with bladder cancer: A meta-analysis","volume":"10","author":"Zhu","year":"2019","journal-title":"Front Pharmacol"},{"key":"key20230628080225_b12-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.euo.2018.07.010","article-title":"PD-L1 expression in men with penile cancer and its association with clinical outcomes","volume":"2","author":"Davidsson","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"key20230628080225_b13-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/j.clgc.2019.10.014","article-title":"PD-L1 and p16 expression in penile squamous cell carcinoma from an endemic region","volume":"18","author":"De Bacco","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"key20230628080225_b14-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s12094-021-02694-7","article-title":"The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis","volume":"24","author":"M\u00fcller","year":"2022","journal-title":"Clin Transl Oncol"},{"key":"key20230628080225_b15-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1093\/annonc\/mdw216","article-title":"Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: Potential opportunities for immunotherapeutic approaches","volume":"27","author":"Udager","year":"2016","journal-title":"Ann Oncol"},{"key":"key20230628080225_b16-BR-19-1-01627","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the eastern cooperative oncology group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"key20230628080225_b17-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: Renal, penile, and testicular tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur Urol"},{"key":"key20230628080225_b18-BR-19-1-01627","author":"Amin"},{"issue":"48","key":"key20230628080225_b19-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-5-48","article-title":"Minimum follow-up time required for the estimation of statistical cure of cancer patients: Verification using data from 42 cancer sites in the SEER database","volume":"5","author":"Tai","year":"2005","journal-title":"BMC Cancer"},{"key":"key20230628080225_b20-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41586-022-04508-4","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer","volume":"603","author":"Shitara","year":"2022","journal-title":"Nature"},{"key":"key20230628080225_b21-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1093\/annonc\/mdz127","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: Results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"key20230628080225_b22-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/PPO.0000000000000299","article-title":"Clinical development of PD-1 in advanced melanoma","volume":"24","author":"Munhoz","year":"2018","journal-title":"Cancer J"},{"key":"key20230628080225_b23-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"874213","key":"key20230628080225_b24-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.874213","article-title":"Immunotherapy in penile squamous cell carcinoma: Present or future? Multi-target analysis of programmed cell death ligand 1 expression and microsatellite instability","volume":"9","author":"Montella","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"key20230628080225_b25-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/s41585-022-00617-x","article-title":"Immune-based therapies in penile cancer","volume":"19","author":"Joshi","year":"2022","journal-title":"Nat Rev Urol"},{"key":"key20230628080225_b26-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.juro.2016.09.088","article-title":"Expression of programmed death ligand 1 in penile cancer is of prognostic value and associated with HPV status","volume":"197","author":"Ottenhof","year":"2017","journal-title":"J Urol"},{"issue":"1013806","key":"key20230628080225_b27-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1013806","article-title":"PD-L1 is associated with the prognosis of penile cancer: A systematic review and meta-analysis","volume":"12","author":"Lu","year":"2022","journal-title":"Front Oncol"},{"issue":"FSO714","key":"key20230628080225_b28-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2021-0044","article-title":"Immune checkpoint inhibitors in penile cancer","volume":"7","author":"Buonerba","year":"2021","journal-title":"Future Sci OA"},{"issue":"1055235","key":"key20230628080225_b29-BR-19-1-01627","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1055235","article-title":"Immune landscape and immunotherapy for penile cancer","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"key20230628080225_b30-BR-19-1-01627","doi-asserted-by":"publisher","first-page":"12305","DOI":"10.12998\/wjcc.v10.i33.12305","article-title":"Conversion therapy for advanced penile cancer with tislelizumab combined with chemotherapy: A case report and review of literature","volume":"10","author":"Long","year":"2022","journal-title":"World J Clin Cases"}],"container-title":["Biomedical Reports"],"original-title":[],"deposited":{"date-parts":[[2023,6,28]],"date-time":"2023-06-28T08:02:33Z","timestamp":1687939353000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/br.2023.1627"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,29]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,5,29]]}},"URL":"https:\/\/doi.org\/10.3892\/br.2023.1627","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,29]]},"article-number":"44"}}